Guidelines for Using Zimeta in Competitive Horses Announced by USEF and AQHA
Policy affects competing members use of the first and only FDA-approved product for control of fever in horses
In November 2019, Zimeta was approved by the U.S. Food and Drug Administration Center for Veterinary Medicine for the control of pyrexia (fever) in horses. Recently, both the United States Equestrian Federation (USEF) and American Quarter Horse Association (AQHA) updated their policies to provide competing members with guidelines for the use of Zimeta.
For both organizations, use of Zimeta will require a properly filed medication report form documenting a 24-hour withdrawal. Additionally, administration of Zimeta will not constitute the use of a second non-steroidal anti-inflammatory drug (NSAID), which is prohibited by USEF and AQHA rules, respectively.1,2
Watch this video to hear Kent Allen, DVM, owner of Virginia Equine Imaging, USEF Veterinary Committee Chairman, and FEI Delegate, for more information about using dipyrone.
Fever is a clinical sign commonly associated with various underlying infectious and non-infectious diseases in the horse, explains Daniel Dreyfuss, DVM, MA, veterinary science liaison at Kindred Biosciences, Inc. (NASDAQ: KIN).
“For equine athletes, fever is an important sign. Fever is a horse’s response to infectious or inflammatory processes. It is important that potentially infectious horses either not travel to the competition or follow appropriate biosecurity protocols if at the competition venue,” Dreyfuss says. “Following the USEF and AQHA
policies gives owners and veterinarians flexibility to use the only NSAID that is FDA-approved to control fever in horses.”
KindredBio is working with the USEF, AQHA, and other equine organizations, to provide the necessary information to determine adequate withdrawal times for Zimeta. This is the first time dipyrone has been FDA approved for veterinary use in the United States. Dipyrone, also known as metamizole, is approved and widely used in many other countries. The Fédération Equestre Internationale (FEI) has established the detection time for dipyrone at 72 hours, which is the shortest established time among NSAIDs approved in the United States.3
For additional questions about the USEF and AQHA policies, please contact the USEF Equine Drugs and Medications Program at 1-800-633-2472 or visit aqha.com. For questions about Zimeta, contact KindredBio Customer Care at 1-888-608-2542.